Vaccination against dengue with the vaccine developed by the Butantan Institute began this Sunday (18) in Botucatu, in the interior of São Paulo. The city is the only one in the state chosen by the Ministry of Health to participate in the study of the impact of the new vaccine on the population.
Named Butantan-DV, the vaccine is the first in the world applied in a single dose and was developed to protect against the four serotypes of the dengue virus. The strategy seeks to accelerate immunization, simplify logistics and reduce operational costs.
In total, the Ministry of Health decided to vaccinate the population aged 15 to 59 in three entire municipalities, before taking the vaccine throughout Brazil. The objective is to evaluate the effectiveness of immunization, the impact on the population and the circulation of the virus in the community.
